Anju has acquired Sylogent

Anju Software, a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent, a provider of software and services for medical affairs and clinical trials.

• The combined company offers the only cloud-based solution for publication planning, which is integrated with industry critical scientific journal and medical conference profiles
• Sylogent CEO Jack Yeager continue to work with Anju to enhance and grow new product offerings with Anju customers and with new customers in Life Sciences

About Anju Software

Anju Software is a leading provider of comprehensive software solutions to the life sciences industry. Anju provides an integrated platform spanning clinical, medical affairs and commercial operations.  Anju solutions are used by large and small pharmaceutical companies, clinical research organizations (CRO), full service agencies and medical device companies.  Data flow between functional areas, seamless communication with third party systems and AI-based data mining solutions to provide customers critical information throughout their ecosystem.

About Sylogent

Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. The company is uniquely positioned to operate within core business units, and across the enterprise, to ensure timely completion of critical information, maximize compliance goals and reduce risk management liability.

About Providence Strategic Growth

Providence is a premier asset management firm with over $40 billion in aggregate capital commitments. Providence pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in over 180 companies and has become a leading equity investment firm focused on the media, communications, education and information industries.